Skip to main content

Table 2 Pooled relative risks of CVDs mortality for categorical and continuous analyses in subgroups

From: Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies

Sub-groups

Triglyceride group (mg/dl)

Per 1 mmol/L TG

<90

90-146

150-199

≥200

 

N*

RR (95% CI)

N*

RR†

N*

RR (95% CI)

N*

RR (95% CI)

N*

RR (95% CI)

Age (year)

  <50

3

0.84 (0.74, 0.96)

4

1.00

4

1.21 (1.06, 1.40)

3

1.20 (0.94, 1.53)

10

1.11 (1.01, 1.22)

  ≥50

7

0.85 (0.68, 1.05)

8

1.00

8

1.08 (0.90, 1.30)

5

1.30 (0.99, 1.69)

12

1.15 (1.09, 1.22)

  P value

 

0.956

   

0.338

 

0.664

 

0.488

Gender

  Male

5

0.86 (0.67, 1.09)

5

1.00

5

1.06 (0.89, 1.30)

5

1.31 (1.12, 1.15)

18

1.10 (1.04, 1.15)

  Female

3

0.76 (0.64, 0.90)

3

1.00

3

1.37 (1.09, 1.71)

2

2.08 (1.44, 3.00)

9

1.40 (1.22, 1.59)

  Mixed

4

1.01 (0.65, 1.56)

6

1.00

6

1.14 (1.10, 1.31)

4

1.26 (0.99, 1.60)

4

1.16 (1.08, 1.25)

  P value

 

0.416

   

0.100

 

0.023

 

0.001

Follow-up (year)

  <12

6

0.81 (0.71, 0.91)

6

1.00

6

1.01 (0.84, 1.19)

4

1.25 (0.84, 1.84)

11

1.14 (1.06, 1.22)

  ≥12

4

0.79 (0.61, 1.02)

4

1.00

6

1.27 (1.13, 1.44)

4

1.25 (1.01, 1.54)

11

1.11 (1.02, 1.21)

  P value

 

0.473

   

0.025

 

0.992

 

0.694

Fast status

  Fast

6

0.89 (0.71, 1.12)

7

1.00

7

1.15 (0.98, 1.35)

4

1.42 (1.22, 1.64)

10

1.10 (1.04, 1.17)

  Nonfast

3

1.00 (0.65, 1.54)

4

1.00

4

1.14 (0.85, 1.46)

4

1.11 (0.85, 1.46)

7

1.12 (1.01, 1.23)

  Others§

1

0.80 (0.69, 0.93)

1

1.00

1

1.15 (0.90, 1.45)

0

-

5

1.19 (1.00, 1.41)

  P value

 

0.646

   

0.843

 

0.122

 

0.821

Geographic location

  Europe/America

7

0.86 (0.73, 1.01)

8

1.00

8

1.17 (1.00, 1.37)

5

1.22 (1.02, 1.55)

18

1.11 (1.05, 1.17)

  Asia-Pacific

3

0.80 (0.70, 0.92)

4

1.00

4

1.20 (0.93, 1.35)

3

1.20 (0.82, 1.77)

4

1.26 (1.05, 1.52)

  P value

 

0.509

   

0.729

 

0.847

 

0.205

Quality score

  <7

4

0.76 (0.65, 0.90)

5

1.00

5

1.01 (0.80, 1.29)

4

1.24 (0.91, 1.68)

8

1.16 (1.04, 1.29)

  7-9

6

0.92 (0.77, 1.05)

7

1.00

7

1.23 (1.09, 1.38)

4

1.25 (0.98, 1.60)

14

1.11 (1.04, 1.19)

  P value

 

0.100

   

0.167

 

0.961

 

0.509

Sample size

  <4000

7

0.84 (0.70, 1.02)

7

1.00

7

1.10 (0.91, 1.32)

4

1.49 (1.21, 1.80)

10

1.14 (1.06, 1.22)

  ≥4000

3

0.83 (0.71, 0.97)

5

1.00

5

1.18 (1.02, 1.38)

4

1.12 (0.84, 1.45)

12

1.13 (1.04, 1.22)

  P value

 

0.910

   

0.541

 

0.100

 

0.883

Free of CVDs at baseline

  Yes

6

0.85 (0.76, 0.96)

7

1.00

7

1.12 (0.92, 1.36)

6

1.20 (0.96, 1.50)

13

1.11 (1.04, 1.20)

  No

4

0.88 (0.67, 1.56)

5

1.00

5

1.16 (1.00, 1.34)

2

1.43 (1.16, 1.76)

9

1.16 (1.09, 1.24)

  P value

 

0.832

   

0.811

 

0.265

 

0.371

Adjustment

  Minimally

4

0.72 (0.55, 0.94)

5

1.00

5

1.44 (1.16, 1.78)

4

1.52 (1.14, 2.02)

7

1.15 (1.08, 1.22)

  Maximally

4

0.87 (0.77, 0.98)

5

1.00

5

1.24 (1.05, 1.46)

4

1.29 (1.01, 1.65)

7

1.05 (0.99, 1.11)

  P value

 

0.207

   

0.271

 

0.398

 

0.033

Adjustment for TC

  Yes

4

0.85 (0.77, 0.94)

4

1.00

4

1.24 (1.07, 1.43)

3

1.27 (0.94, 1.71)

14

1.09 (1.03, 1.16)

  No

6

0.82 (0.61, 1.09)

8

1.00

8

1.06 (0.89, 1.26)

5

1.25 (0.97, 1.61)

8

1.21 (1.10, 1.34)

  P value

 

0.810

   

0.169

 

0.927

 

0.078

Adjustment for HDL

  Yes

3

0.81 (0.72, 0.91)

3

1.00

3

1.23 (1.04, 1.47)

1

1.52 (1.14, 2.02)

3

1.10 (1.03, 1.19)

  No

7

0.84 (0.68, 1.04)

9

1.00

9

1.09 (0.94, 1.27)

7

1.21 (1.00, 1.47)

19

1.13 (1.06, 1.20)

  P value

 

0.734

   

0.313

 

0.200

 

0.679

  1. *The number of cohorts.
  2. †Reference group.
  3. §Others included mixed and unknown ones.
  4. RR, relative risk; CI, confidence interval; CVDs: cardiovascular diseases; HDL: high-density lipoprotein.
  5. TG: triglycerides; TC: total cholesterol.